UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Dec

    16

    Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

    Dec

    10

    UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis